MilliporeSigma invests $286M in U.S. drug safety testing
by CM Staff
This will help increase the company's ability to conduct biosafety testing and analytical development services.
MilliporeSigma scientist counts cells in a cell culture lab in Rockville, MD, where the company is investing € 290 million to address growing global demand for biosafety testing.
BURLINGTON — MilliporeSigma’s Life Science business sector is investing more than $286 million in its biosafety testing capacity at the company’s site in Rockville, Maryland, U.S.
The company says this will help increase the company’s ability to conduct biosafety testing and analytical development services, which the industry considers critical and fundamental requirements of the commercialization process to ensure the safety of medicines. MilliporeSigma says global demand for these services is growing at a double-digit rate.
“MilliporeSigma is harnessing its broad portfolio of modern technologies and enabling services to help ensure the safety of the world’s medicines. These significant investments in Rockville and other sites across our global network will help us meet growing demand for the robust testing studies that biologics manufacturers depend upon to comply with stringent regulatory guidelines,” said Belén Garijo, chair of the executive board and CEO of Merck KGaA, Darmstadt, Germany, in a statement.
Contract testing and the newly formed Millipore® CTDMO Services are part of the life science services business unit, which together with the process solutions business is one of Merck KGaA, Darmstadt, Germany’s “Big 3” growth drivers. The company aims to increase its Group sales to approximately € 25 billion by 2025.
“This is a prime example of our focus on sustainable growth in areas with strong underlying upwards dynamics.”
